Biogen Inc. [NASDAQ: BIIB] price plunged by -28.17 percent to reach at -$92.64. The company report on November 10, 2020 that Rosen, A Global and Leading Law Firm, Announces Investigation of Securities Claims Against Biogen Inc.; Encourages Investors with Losses in Excess of $500K to Contact Firm – BIIB.
New York, New York–(Newsfile Corp. – November 9, 2020) – Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) resulting from allegations that Biogen may have issued materially misleading business information to the investing public.
On November 6, 2020, Biogen trading was halted before the Company’s meeting with the U.S. Food and Drug Administration (“FDA”).
A sum of 9223786 shares traded at recent session while its average daily volume was at 1.47M shares. Biogen Inc. shares reached a high of $239.50 and dropped to a low of $223.25 until finishing in the latest session at $236.26.
The one-year BIIB stock forecast points to a potential upside of 24.66. The average equity rating for BIIB stock is currently 2.60, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Biogen Inc. [BIIB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BIIB shares is $313.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BIIB stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Biogen Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 09, 2020. The new note on the price target was released on November 09, 2020, representing the official price target for Biogen Inc. stock. Previously, the target price had yet another raise to $240, while BofA Securities analysts kept a Underperform rating on BIIB stock.
The Average True Range (ATR) for Biogen Inc. is set at 22.69, with the Price to Sales ratio for BIIB stock in the period of the last 12 months amounting to 2.55. The Price to Book ratio for the last quarter was 3.45, with the Price to Cash per share for the same quarter was set at 23.26. Price to Free Cash Flow for BIIB in the course of the last twelve months was 5.71 with Quick ratio for the last quarter at 1.80.
BIIB Stock Performance Analysis:
Biogen Inc. [BIIB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.27. With this latest performance, BIIB shares dropped by -17.66% in over the last four-week period, additionally sinking by -27.97% over the last 6 months – not to mention a drop of -17.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIIB stock in for the last two-week period is set at 42.34, with the RSI for the last a single of trading hit 40.82, and the three-weeks RSI is set at 42.86 for Biogen Inc. [BIIB]. The present Moving Average for the last 50 days of trading for this stock 275.59, while it was recorded at 283.36 for the last single week of trading, and 291.93 for the last 200 days.
Insight into Biogen Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Biogen Inc. [BIIB] shares currently have an operating margin of +45.85 and a Gross Margin at +80.97. Biogen Inc.’s Net Margin is presently recorded at +46.32.
Return on Total Capital for BIIB is now 30.09, given the latest momentum, and Return on Invested Capital for the company is 31.67. Return on Equity for this stock inclined to 44.64, with Return on Assets sitting at 22.42. When it comes to the capital structure of this company, Biogen Inc. [BIIB] has a Total Debt to Total Equity ratio set at 48.27. Additionally, BIIB Total Debt to Total Capital is recorded at 32.56, with Total Debt to Total Assets ending up at 23.65. Long-Term Debt to Equity for the company is recorded at 36.51, with the Long-Term Debt to Total Capital now at 24.62.
Reflecting on the efficiency of the workforce at the company, Biogen Inc. [BIIB] managed to generate an average of $795,743 per employee. Receivables Turnover for the company is 5.13 with a Total Asset Turnover recorded at a value of 0.48.Biogen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.10.
BIIB Stock EPS
With the latest financial reports released by the company, Biogen Inc. posted 8.34/share EPS, while the average EPS was predicted by analysts to be reported at 8.02/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BIIB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biogen Inc. go to -4.92%.
Biogen Inc. [BIIB] Insider Position Details
There are presently around $31,929 million, or 90.50% of BIIB stock, in the hands of institutional investors. The top three institutional holders of BIIB stocks are: PRIMECAP MANAGEMENT CO/CA/ with ownership of 15,631,932, which is approximately -2.092% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 14,463,279 shares of the stock with an approximate value of $3.42 billion in BIIB stocks shares; and VANGUARD GROUP INC, currently with $3.04 billion in BIIB stock with ownership of nearly -9.567% of the company’s market capitalization.
Positions in Biogen Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 431 institutional holders increased their position in Biogen Inc. [NASDAQ:BIIB] by around 7,958,006 shares. Additionally, 527 investors decreased positions by around 16,826,577 shares, while 202 investors held positions by with 110,359,581 shares. The mentioned changes placed institutional holdings at 135,144,164 shares, according to the latest SEC report filing. BIIB stock had 95 new institutional investments in for a total of 653,373 shares, while 107 institutional investors sold positions of 1,481,056 shares during the same period.